Show simple item record

dc.contributor.authorHorsch, D
dc.contributor.authorKulke, M
dc.contributor.authorCaplin, M
dc.contributor.authorAnthony, L
dc.contributor.authorBergsland, E
dc.contributor.authorOberg, K
dc.contributor.authorWarner, R
dc.contributor.authorKunz, P
dc.contributor.authorGrande, E
dc.contributor.authorValle, Juan W
dc.contributor.authorDillon, J
dc.contributor.authorLapuerta, P
dc.contributor.authorBanks, P
dc.contributor.authorJackson, S
dc.contributor.authorPavel, M
dc.date.accessioned2018-05-02T10:58:17Z
dc.date.available2018-05-02T10:58:17Z
dc.date.issued2018
dc.identifier.citationEfficacy and safety of telotristat ethyl in patients With carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period. 2018, 47(3):341-342 Pancreasen
dc.identifier.urihttp://hdl.handle.net/10541/620963
dc.language.isoenen
dc.titleEfficacy and safety of telotristat ethyl in patients With carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentZentralklinik Bad Berkaen
dc.identifier.journalPancreasen


This item appears in the following Collection(s)

Show simple item record